Tissue penetration of antimicrobials: Difference between revisions
From IDWiki
No edit summary |
mNo edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 251: | Line 251: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" |±[[CiteRef::jodlowski2020do]] |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| Line 284: | Line 284: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
|- |
|- |
||
! colspan="8" |Antifungals[[CiteRef::felton2014ti]] |
|||
! colspan="8" |Antifungals<ref>Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014 Jan;27(1):68-88. doi: 10.1128/CMR.00046-13. PMID: 24396137; PMCID: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910906/ PMC3910906].</ref> |
|||
|- |
|- |
||
| rowspan="3" |[[Azoles]] |
| rowspan="3" |[[Azoles]] |
||
| Line 296: | Line 296: | ||
|- |
|- |
||
|[[itraconazole]] |
|[[itraconazole]] |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" |± |
|||
|± |
|||
| style="text-align:center" |– |
|||
|– |
|||
| style="text-align:center" | + |
|||
| + |
|||
| style="text-align:center" |– |
|||
|– |
|||
| style="text-align:center" | |
|||
| |
|||
|- |
|- |
||
|[[voriconazole]] |
|[[voriconazole]] |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" |± |
|||
|± |
|||
| style="text-align:center" |± |
|||
|± |
|||
| style="text-align:center" |± |
|||
|± |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
|- |
|- |
||
| rowspan="3" |[[Echinocandins]] |
| rowspan="3" |[[Echinocandins]] |
||
|[[anidulafungin]] |
|||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| style="text-align:center" |± |
| style="text-align:center" |± |
||
| Line 321: | Line 321: | ||
|- |
|- |
||
|[[caspofungin]] |
|[[caspofungin]] |
||
| style="text-align:center" | + |
|||
| + |
|||
| style="text-align:center" |– |
|||
|– |
|||
| style="text-align:center" |– |
|||
|– |
|||
| style="text-align:center" |± |
|||
|± |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
|- |
|- |
||
|[[micafungin]] |
|[[micafungin]] |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" |± |
|||
|± |
|||
| style="text-align:center" |– |
|||
|– |
|||
| style="text-align:center" |± |
|||
|± |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
|- |
|- |
||
| rowspan="2" |[[Polyenes]] |
| rowspan="2" |[[Polyenes]] |
||
|deoxycholate [[amphotericin B]] |
|deoxycholate [[amphotericin B]] |
||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" |– |
|||
|– |
|||
| style="text-align:center" | + |
|||
| + |
|||
| style="text-align:center" | |
|||
| |
|||
| style="text-align:center" | |
|||
| |
|||
|- |
|- |
||
|liposomal [[amphotericin B]] |
|liposomal [[amphotericin B]] |
||
Latest revision as of 17:51, 19 September 2024
Summary
- † if inflammation present
- ‡ very low levels, but likely enough for Enterococcus
Specific Tissues
Central Nervous System
- Reviewed in 3
| Class | Antimicrobial | CSF Penetration (AUC) | With Meningeal Inflammation |
|---|---|---|---|
| Antibiotics | |||
| penicillins | overall | 2% | 2% |
| ampicillin | |||
| amoxicillin | 6% | ||
| cloxacillin | 0.87% | ||
| piperacillin | 3% | 32% | |
| beta lactamase inhibitors | overall | 7% | 10% |
| clavulanate | 4% | 8% | |
| tazobactam | 11% | ||
| cephalosporins | overall | 0.7 to 10% | 15% |
| cefotaxime | 12% | 4 to 17% | |
| ceftriaxone | 0.7% | ||
| ceftazidime | 0.6% | ||
| carbapenems | overall | 20% | 30% |
| imipenem | 14% | ||
| meropenem | 5 to 25% | 39% | |
| aminoglycosides | overall | 20% | |
| fluoroquinolones | overall | 30 to 70% | 70 to 90% |
| ciprofloxacin | 24 to 43% | 92% | |
| levofloxacin | 71% | ||
| moxifloxacin | 46% | 79% | |
| chloramphenicol | 60 to 70% | 60 to 70% | |
| macrolides | clarithromycin | 18% | |
| tetracyclines | doxycycline | 20% | 20% |
| fosfomycin | 18% | ||
| linezolid | 90% | ||
| metronidazole | 87% | ||
| rifamycins | rifampin | 22% | |
| trimethoprim-sulfamethoxazole | trimethoprim | 18% | 42 to 51% |
| sulfamethoxazole | 12% | 24 to 30% | |
| glycopeptides | vancomycin | 14 to 18% | 30% |
| antituberculosis medications | isoniazid | 86% | |
| Antivirls | |||
| anti-herpes nucleoside analogues | acyclovir | 31% | |
| valacyclovir | 19% | ||
| foscarnet | 27 to 43% | 23 to 66% | |
| HIV antiretrovirals | abacavir | 35% | |
| zidovudine | 75% | ||
| indinavir | 6 to 15% | ||
| lopinavir | 29% | ||
| Antifungals | |||
| flucytosine | 74% | ||
| azoles | fluconazole | 86% | |
| voriconazole | 46% | ||
| polyenes | amphotericin B | low | |
| Antiparasitics | |||
| albendazole | 38 to 43% | ||
| praziquantel | 24% | ||
| sulfadiazine | 27 to 33% | ||
Prostate
- Poorly penetrated by most antibiotics
- Penetration is higher with a high concentration gradient, high lipid solubility, low degree of ionization, high dissociation constant, low protein binding, and small molecular size
- Fluoroquinolones are the mainstay of therapy, though there is increasing resistance
- TMP-SMX often used, though conflicting data about its penetration into the prostate
- Minocycline, doxycycline, and macrolides achieve high levels in the prostate but are rarely indicated for the causative organisms
- Third-generation cephalosporins and carbapenems can be used
- Piperacillin, aztreonam, imipenem, and some aminoglycosides are likely useful
Bone
- Essentially all antibiotics achieve similar bone-to-serum levels, with the exception of oral β-lactams which nevertheless have no worse outcomes4
Eye
- Ocular compartments include anterior and posterior
- Anterior includes aqeous humour, and is best accessed using topical medications
- Posterior includes vitreous humour, retina, and choroid, and is best accessed using intravitreal or systemic medications
- Penetration of systemic antimicrobials into retina and vitreous is poor (~0 to 2%), but is better with inflammation5
- Preferred agents for vitreal penetration include meropenem, linezolid, and moxifloxacin
- Agents that are likely effective, especially when inflammation is present, include vancomycin, cefazolin, ceftriaxone, ceftazidime, imipenem, and trimethoprim-sulfamethoxazole, and possible daptomycin and rifampin
- Agents that do not reach adequate levels include ciprofloxacin, levofloxacin, aminoglycosides, aminopenicillins, piperacillin, cefepime, and clarithromycin
| Class | Antimicrobial | Retinal Penetration | Vitreal Penetration | Ref |
|---|---|---|---|---|
| Antibiotics | ||||
| penicillins | ampicillin | below MIC in non-inflamed rabbit eyes | 5 | |
| amoxicillin | 2% (below MIC) in non-inflamed rabbit eyes | 5 | ||
| piperacillin | undetectable in inflamed human eyes | 5 | ||
| cephalosporins | cefazolin | above MIC in inflamed rabbit eyes | 5 | |
| ceftriaxone | 4% in non-inflamed human eyes | 5 | ||
| ceftazidime | 30% in inflamed rabbit eyes | 5 | ||
| cefipime | 8% in non-inflamed human eyes | 5 | ||
| carbapenems | imipenem | 8 to 10% in non-inflamed human eyes | 5 | |
| meropenem | 30% in non-inflamed human eyes | 5 | ||
| oxazolidinones | linezolid | 30 to 80% in non-inflamed human eyes | 5 | |
| vancomycin | above MIC in inflamed rabbit eyes | 5 | ||
| daptomycin | 30% in inflamed human eyes | 5 | ||
| aminoglycosides | amikacin | below MIC in inflamed rabbit eyes | 5 | |
| gentamicin | below MIC in inflamed rabbit eyes | 5 | ||
| fluoroquinolones | ciprofloxacin | below MIC in non-inflamed human eyes | 5 | |
| levofloxacin | 30% but below MIC in non-inflamed human eyes | 5 | ||
| moxifloxacin | 10 to 40% and above MIC in non-inflamed human eyes | 5 | ||
| Antifungals | ||||
| azoles | fluconazole | 40 to 50% | 40 to 50% | 62 |
| itraconazole | 10% in inflamed eyes | 2 | ||
| posaconazole | 20% in inflamed eyes | 2 | ||
| voriconazole | 40 to 100% | 2 | ||
| flucytosine | 40 to 100% | 2 | ||
| polyenes | liposomal amphotericin B | only detectable in inflamed eyes | 2 | |
| echinocandins | echinocandins | very low penetration | 2 | |
| micafungin | excellent | undetectable | 62 | |
| Antivirals | ||||
| acyclovir | above IC | |||
| valacyclovir | 20 to 30%, above IC in non-inflamed human eyes | 7 | ||
| ganciclovir | close to IC | |||
| foscarnet | 100% | 10%, close to IC | 8 | |
References
- ^ Cornelia B. Landersdorfer, Jürgen B. Bulitta, Martina Kinzig, Ulrike Holzgrabe, Fritz Sörgel. Penetration of Antibacterials into Bone. Clinical Pharmacokinetics. 2009;48(2):89-124. doi:10.2165/00003088-200948020-00002.
- a b c d e f g h i j k l m n o p q r L. Brockhaus, D. Goldblum, L. Eggenschwiler, S. Zimmerli, C. Marzolini. Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics. Clinical Microbiology and Infection. 2019;25(11):1364-1369. doi:10.1016/j.cmi.2019.01.017.
- a b Takashi Suzuki, Toshihiko Uno, Guangming Chen, Yuichi Ohashi. Ocular distribution of intravenously administered micafungin in rabbits. Journal of Infection and Chemotherapy. 2008;14(3):204-207. doi:10.1007/s10156-008-0612-5.
- a b c d e f g h Timothy Felton, Peter F. Troke, William W. Hope. Tissue Penetration of Antifungal Agents. Clinical Microbiology Reviews. 2014;27(1):68-88. doi:10.1128/cmr.00046-13.
- ^ Tony H. Huynh, Mark W. Johnson, Grant M. Comer, Douglas N. Fish. Vitreous Penetration of Orally Administered Valacyclovir. American Journal of Ophthalmology. 2008;145(4):682-686. doi:10.1016/j.ajo.2007.11.016.
- ^ Luis F. López-Cortés, R. Ruiz-Valderas, M. J. Lucero-Muñoz, E. Cordero, M. T. Pastor-Ramos, J. Marquez. Intravitreal, Retinal, and Central Nervous System Foscarnet Concentrations after Rapid Intravenous Administration to Rabbits. Antimicrobial Agents and Chemotherapy. 2000;44(3):756-759. doi:10.1128/aac.44.3.756-759.2000.
